![Thomas Barnes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Barnes
Directeur Général chez
Exsilio Therapeutics, Inc.
Profil
Thomas M.
Barnes is President, Chief Executive Officer & Director at Averna Therapeutics, Inc. since 2025.
Dr. Barnes is Entrepreneur Partner at MPM BioImpact LLC since 2020.
Former roles include Chief Executive Officer & Director at Orna Therapeutics, Inc., Director-Genomic Pharmacology at Millennium Pharmaceuticals, Inc., Senior Vice President-Discovery at Ore Pharmaceuticals, Inc., Vice President-Discovery at Sesen Bio, Inc., and Senior VP-Innovative Sciences & eXtellia at Intellia Therapeutics, Inc. Education includes a doctorate from the University of Cambridge conferred in 1991 and an undergraduate degree from The University of Sydney conferred in 1981.
Postes actifs de Thomas Barnes
| Sociétés | Poste | Début |
|---|---|---|
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Private Equity Investor | 01/02/2020 |
Exsilio Therapeutics, Inc.
 Exsilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops genomic medicines | Directeur Général | 28/01/2025 |
Anciens postes connus de Thomas Barnes
| Sociétés | Poste | Fin |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2013 |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Develops RNA therapeutics | Directeur Général | - |
| INTELLIA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | - |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Corporate Officer/Principal | - |
Ore Pharmaceuticals, Inc.
 Ore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Corporate Officer/Principal | - |
Formation de Thomas Barnes
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
95
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Sydney
 The University of Sydney Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ore Pharmaceuticals, Inc.
Ore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics to treat eye diseases | Health Technology |
Intellia Therapeutics, Inc.
 Intellia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel and potentially curative therapeutics | Health Technology |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Develops RNA therapeutics | Health Technology |
Exsilio Therapeutics, Inc.
Exsilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops genomic medicines | Health Technology |
